Combinatorial screening algorithm to engineer multiepitope subunit vaccine targeting human T‐lymphotropic virus‐1 infection

Pandey, Rajan Kumar; Ojha, Rupal; Chatterjee, Nina; Upadhyay, Nitesh; Mishra, Amit; Prajapati, Vijay Kumar

doi:10.1002/jcp.27531

Cited by 7 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The polyepitope‐based vaccines leveraging such mechanisms of activating different immune cell types have recently been put forward for consideration by several researchers, against the number of infective diseases, such as Kaposi sarcoma (Chauhan et al, 2019), Epstein–Barr virus (Ojha et al, 2019), Zika virus (Kumar Pandey, Ojha, Mishra, & Kumar Prajapati, 2018), cytomegalovirus (Chauhan & Singh, 2020), human T‐lymphotropic virus‐1 (Pandey et al, 2019), Ebola virus (Bazhan et al, 2019), and so forth.…”

Section: Resultsmentioning

confidence: 99%

“…The amino acid sequence of the finalized vaccine model was further subjected to in silico immune simulations, revealing that it Epstein-Barr virus (Ojha et al, 2019), Zika virus (Kumar Pandey, Ojha, Mishra, & Kumar Prajapati, 2018), cytomegalovirus (Chauhan & Singh, 2020), human T-lymphotropic virus-1 (Pandey et al, 2019), Ebola virus (Bazhan et al, 2019), and so forth.…”

Section: T-cell Ifn-γ and B-cell Epitope Recognitionmentioning

confidence: 99%

See 1 more Smart Citation

Excavating SARS‐coronavirus 2 genome for epitope‐based subunit vaccine synthesis using immunoinformatics approach

Chauhan

Rungta

Rawat

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Since the outbreak of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in December 2019 in China, there has been an upsurge in the number of deaths and infected individuals throughout the world, thereby leading to the World Health Organization declaration of a pandemic. Since no specific therapy is currently available for the same, the present study was aimed to explore the SARS-CoV-2 genome for the identification of immunogenic regions using immunoinformatics approach. A series of computational tools were applied in a systematic way to identify the epitopes that could be utilized in vaccine development. The screened-out epitopes were passed through several immune filters, such as promiscuousity, conservancy, antigenicity, nonallergenicity, population coverage, nonhomologous to human proteins, and affinity with human leukocyte antigen alleles, to screen out the best possible ones. Further, a construct comprising 11 CD4, 12 CD8, 3 B cell, and 3 interferon-γ epitopes, along with an adjuvant β-defensin, was designed in silico, resulting in the formation of a multiepitope vaccine. The in silico immune simulation and population coverage analysis of the vaccine sequence showed its capacity to elicit cellular, humoral, and innate immune cells and to cover up a worldwide population of more than 97%. Further, the interaction analysis of the vaccine construct with Toll-like receptor 3 (immune receptor) was carried out by docking and dynamics simulations, revealing high affinity, constancy, and pliability between the two. The overall findings suggest that the vaccine may be highly effective, and is therefore required to be tested in the lab settings to evaluate its efficacy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: T-cell Ifn-γ and B-cell Epitope Recognitionmentioning

confidence: 99%

Excavating SARS‐coronavirus 2 genome for epitope‐based subunit vaccine synthesis using immunoinformatics approach

Chauhan

Rungta

Rawat

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…The immunoinformatic servers provides an easiest way, which curtails the experimental effort for the epitope identification. In the field of vaccinology, many researchers with the help of reverse vaccinology approach have proved the antigenicity of peptide vaccines in contradiction of various infectious diseases (Dikhit et al, 2017;Muruato et al, 2017;Ojha et al, 2018;Pandey et al, 2019).…”

Section: Antigenic Mhc Class II Epitopes Prediction From the Covid-19mentioning

confidence: 99%

High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19

Ojha

Gupta

Naik

et al. 2020

European Journal of Pharmaceutical Sciences

Self Cite

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

“…All in-vivo studies were animal model with animals such as mouse, rat, rabbit, and monkey. The major protein vaccine constructs assessed in these studies were comprised of Tax peptide in 15 studies [ 41 , 44 , 47 – 49 , 51 , 54 – 56 , 63 , 64 , 66 , 67 , 73 – 75 ], Glycoprotein peptide (GP) in 9 studies [ 33 , 35 , 38 , 48 , 49 , 58 , 66 , 72 , 75 ], GAG peptide in 5 studies [ 47 – 49 , 63 , 66 ], POL peptide in 3 studies [ 47 , 63 , 66 ], REX and HBZ peptides each one in 1 study, respectively [ 47 , 63 ].…”

Section: Resultsmentioning

confidence: 99%

Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies

et al. 2023

View full text Add to dashboard Cite

Background Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning of future preventative actions to reduce HTLV-1 infection and its consequences would be essential. Methods MEDLINE, Scopus, Web of Science, and Clinicaltrials.gov were searched from each database's inception through March 27, 2022. All original articles focusing on developing an HTLV-1 vaccine candidate were included. Results A total of 47 studies were included. They used a variety of approaches to develop the HTLV-1 vaccine, including DNA-based, dendritic-cell-based, peptide/protein-based, and recombinant vaccinia virus approaches. The majority of the research that was included utilized Tax, Glycoprotein (GP), GAG, POL, REX, and HBZ as their main peptides in order to develop the vaccine. The immunization used in dendritic cell-based investigations, which were more recently published, was accomplished by an activated CD-8 T-cell response. Although there hasn't been much attention lately on this form of the vaccine, the initial attempts to develop an HTLV-1 immunization depended on recombinant vaccinia virus, and the majority of results seem positive and effective for this type of vaccine. Few studies were conducted on humans. Most of the studies were experimental studies using animal models. Adenovirus, Cytomegalovirus (CMV), vaccinia, baculovirus, hepatitis B, measles, and pox were the most commonly used vectors. Conclusions This systematic review reported recent progression in the development of HTLV-1 vaccines to identify candidates with the most promising preventive and therapeutic effects.

show abstract

Combinatorial screening algorithm to engineer multiepitope subunit vaccine targeting human T‐lymphotropic virus‐1 infection

Cited by 7 publications

References 46 publications

Excavating SARS‐coronavirus 2 genome for epitope‐based subunit vaccine synthesis using immunoinformatics approach

Excavating SARS‐coronavirus 2 genome for epitope‐based subunit vaccine synthesis using immunoinformatics approach

High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19

Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies

Contact Info

Product

Resources

About